PeptiDream Inc (PeptiDream) is a biopharmaceutical company that discovers and develops non-standard peptide therapeutics addressing unmet medical needs. The company is investigating peptide drug conjugates (PDC), peptides and small molecule-based drugs. PeptiDream pipeline products include PD-L1 - (BMS-986229), CD38 - (BHV-1100 + NK cells), S2-protein (PA-001), GhR (AZP-3813), glypican-3, myostatin, TfR, c-Kit and HA- protein. Its pipeline treats oncology, multiple myeloma, covid-19, acromegaly, liver cancer, muscle disorders, neuromuscular disorders, allergic condition and influenza. PeptiDream is headquartered in Kawasaki, Kanagawa, Japan.
Headquarters
Japan
Address
3-25-23, Tono-Machi, Kawasaki-Ku, Kawasaki-Shi, Kanagawa, 210-0821
Website
www.peptidream.com
Telephone
81 44 2701300
No of Employees
603
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4587 (TYO)
Revenue (2022)
$212.1M
6.9%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-59.8%
(2022 vs 2021)
Market Cap*
$1.3B
Net Profit Margin (2022)
XYZ
-62.4%
(2022 vs 2021)
* As of and is in US$
PeptiDream Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| PD-L1 - (BMS-986229) Oncology |
| CD38 - ( BHV-1100 + NK Cells) - Multiple Myeloma |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In September, the company entered into an agreement with Genentech for the discovery and development of novel macrocyclic peptide-radioisotope drug conjugates. |
| 2023 | Contracts/Agreements | In July, the company and Astellas Pharma signed a research collaboration and license agreement to discover novel protein degraders for two targets selected by Astellas. |
| 2023 | Contracts/Agreements | In March, the company entered into an agreement with Ono Pharmaceutical for the creation and development of a special cyclic peptide drug. |
Competitor Comparison
| Key Parameters | PeptiDream Inc | OncoTherapy Science Inc | AnGes Inc | BrightPath Biotherapeutics Co Ltd | Jitsubo Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Kawasaki-Shi | Kawasaki-Shi | Ibaraki-Shi | Chiyoda-Ku | Yokohama |
| State/Province | Kanagawa | Kanagawa | Osaka | Tokyo | Kanagawa |
| No. of Employees | 603 | 60 | 138 | 32 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Reed Patrick Ph.D | President; Director; Chief Executive Officer | Executive Board | - | - |
| Kinjo Scripture Ph.D. | Chief Financial Officer; Executive Vice President | Senior Management | 2018 | - |
| Keiichi Masuya Ph.D | Chief Operating Officer; Executive Vice President | Senior Management | - | - |
| Masato Murakami Ph.D. | Chief Medical Officer | Senior Management | 2022 | - |
| Michio Sasaoka Ph.D. | Director | Non Executive Board | 2012 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward